We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Sargramostim, an innate immune system modulator, has been FDA approved for treating leukopenia for many years. Sargramostim has been investigated in this phase 2 study to determine if it can safely halt or reduce cognitive decline and brain pathology in participants with mild-to-moderate Alzheimer’s disease. Prof. Huntington Potter (University of Colorado, Denver, MS, USA) joins […]
Prof. Jackie Palace (Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, UK) joins us for Rare Disease Day to discuss neuromyelitis optica spectrum disorder (NMOSD), how it differs from multiple sclerosis, and the major barriers patients face in diagnosis and treatment. She also discusses the use of multidisciplinary teams in providing support and advice to […]
Megan Hunter is living with myasthenia gravis (MG) and joins us for Rare Disease Day to discuss her initial symptoms, the journey to diagnosis and the treatment regimen that followed. She also discusses her coping strategies and the impact that treatment and living with MG has had on her life. Megan reminds us that every […]
Shekita Green (USA) is living with neuromyelitis optica spectrum disorder (NMOSD) and joins us for Rare Disease Day to share her experiences. She discusses her initial symptoms, the journey to diagnosis and her current treatment regimen. Shekita also talks about the strategies she uses to reduce the impact of NMOSD on her day-to-day life. Touch […]
Prof. Said Beydoun (Keck Medical Center of USC, University of Southern California, CA, USA), Editor-in-Chief of touchREVIEWS in Neurology, joins us for Rare Disease Day to share his perspectives and experiences in treating people with myasthenia gravis. In this interview, he discusses the impact myasthenia gravis has on quality of life, the key symptoms and […]
The World Congress on Controversies in Neurology (CONy) provides a platform for international experts to discuss and compare experience in many areas of neurology and in treatment of neurological diseases, thus closing the gap between the expansion of knowledge and its dissemination and use. By having this debate style structure, the congress has become a […]
touchNEUROLOGY met with Professor Mary Koenig (McGovern Medical School, UTHealth, Houston, TX, USA) to discuss the efficacy and safety findings from the phase 2 clinical study investigating oral ganaxolone for the treatment of tuberous sclerosis complex (NCT04285346). The abstract ‘Phase 2 Open-label Clinical Study Evaluating Oral Ganaxolone for the Treatment of Seizures Associated with Tuberous […]
It was a great pleasure to meet with both Dr Monica Ferrer Socorro (NYU Langone Health, New York City, NY, USA) and Prof. Jacqueline French (NYU Grossman School of Medicine, New York City, NY, USA) to discuss a retrospective analysis investigating focal epilepsy, its clinical presentation in adolescents, highlighting disproportionate delay to diagnosis experienced by […]
touchNEUROLOGY met with Prof. Michael Sperling (Thomas Jefferson University, Philadelphia, PA, USA) to discuss a subgroup analysis from a phase 3 safety study investigating the use of diazepam nasal spray in patients with seizure clusters concomitantly receiving clobazam. Diazepam nasal spray is an FDA-approved nasal spray version of diazepam, indicated for the treatment of acute, […]
Get the latest clinical insights from touchNEUROLOGY